Chronic myelogenous leukemia

Susan O'Brien, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P DeVetten, Peter D. Emanuel, Harry P. Erba, Peter L. Greenberg, Joseph O. Moore, Donna Przepiorka, Jerald P. Radich, Russell J. Schilder, Paul Shami, B. Douglas Smith, David S. Snyder, Robert J. Soiffer, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

Original languageEnglish (US)
Pages (from-to)474-496
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number5
StatePublished - May 1 2007

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem Cell Transplantation
Cytogenetics
Interferons
Leukemia
Guidelines
Therapeutics
Imatinib Mesylate
Dasatinib

Keywords

  • Chronic myelogenous leukemia
  • Desatinib
  • Imatinib
  • Karyotyping
  • NCCN clinical practice guidelines
  • Polymerase chain reaction
  • Transplantation

ASJC Scopus subject areas

  • Oncology

Cite this

O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., DeVetten, M. P., Emanuel, P. D., ... Wetzler, M. (2007). Chronic myelogenous leukemia. JNCCN Journal of the National Comprehensive Cancer Network, 5(5), 474-496.

Chronic myelogenous leukemia. / O'Brien, Susan; Berman, Ellin; Bhalla, Kapil; Copelan, Edward A.; DeVetten, Marcel P; Emanuel, Peter D.; Erba, Harry P.; Greenberg, Peter L.; Moore, Joseph O.; Przepiorka, Donna; Radich, Jerald P.; Schilder, Russell J.; Shami, Paul; Smith, B. Douglas; Snyder, David S.; Soiffer, Robert J.; Tallman, Martin S.; Talpaz, Moshe; Wetzler, Meir.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 5, 01.05.2007, p. 474-496.

Research output: Contribution to journalReview article

O'Brien, S, Berman, E, Bhalla, K, Copelan, EA, DeVetten, MP, Emanuel, PD, Erba, HP, Greenberg, PL, Moore, JO, Przepiorka, D, Radich, JP, Schilder, RJ, Shami, P, Smith, BD, Snyder, DS, Soiffer, RJ, Tallman, MS, Talpaz, M & Wetzler, M 2007, 'Chronic myelogenous leukemia', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 5, pp. 474-496.
O'Brien S, Berman E, Bhalla K, Copelan EA, DeVetten MP, Emanuel PD et al. Chronic myelogenous leukemia. JNCCN Journal of the National Comprehensive Cancer Network. 2007 May 1;5(5):474-496.
O'Brien, Susan ; Berman, Ellin ; Bhalla, Kapil ; Copelan, Edward A. ; DeVetten, Marcel P ; Emanuel, Peter D. ; Erba, Harry P. ; Greenberg, Peter L. ; Moore, Joseph O. ; Przepiorka, Donna ; Radich, Jerald P. ; Schilder, Russell J. ; Shami, Paul ; Smith, B. Douglas ; Snyder, David S. ; Soiffer, Robert J. ; Tallman, Martin S. ; Talpaz, Moshe ; Wetzler, Meir. / Chronic myelogenous leukemia. In: JNCCN Journal of the National Comprehensive Cancer Network. 2007 ; Vol. 5, No. 5. pp. 474-496.
@article{1222e4032ae24577b7fc6f80aa31ad1d,
title = "Chronic myelogenous leukemia",
abstract = "Chronic myelogenous leukemia (CML) accounts for 15{\%} of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.",
keywords = "Chronic myelogenous leukemia, Desatinib, Imatinib, Karyotyping, NCCN clinical practice guidelines, Polymerase chain reaction, Transplantation",
author = "Susan O'Brien and Ellin Berman and Kapil Bhalla and Copelan, {Edward A.} and DeVetten, {Marcel P} and Emanuel, {Peter D.} and Erba, {Harry P.} and Greenberg, {Peter L.} and Moore, {Joseph O.} and Donna Przepiorka and Radich, {Jerald P.} and Schilder, {Russell J.} and Paul Shami and Smith, {B. Douglas} and Snyder, {David S.} and Soiffer, {Robert J.} and Tallman, {Martin S.} and Moshe Talpaz and Meir Wetzler",
year = "2007",
month = "5",
day = "1",
language = "English (US)",
volume = "5",
pages = "474--496",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Chronic myelogenous leukemia

AU - O'Brien, Susan

AU - Berman, Ellin

AU - Bhalla, Kapil

AU - Copelan, Edward A.

AU - DeVetten, Marcel P

AU - Emanuel, Peter D.

AU - Erba, Harry P.

AU - Greenberg, Peter L.

AU - Moore, Joseph O.

AU - Przepiorka, Donna

AU - Radich, Jerald P.

AU - Schilder, Russell J.

AU - Shami, Paul

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Soiffer, Robert J.

AU - Tallman, Martin S.

AU - Talpaz, Moshe

AU - Wetzler, Meir

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

AB - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

KW - Chronic myelogenous leukemia

KW - Desatinib

KW - Imatinib

KW - Karyotyping

KW - NCCN clinical practice guidelines

KW - Polymerase chain reaction

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=34249288276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249288276&partnerID=8YFLogxK

M3 - Review article

C2 - 17509252

AN - SCOPUS:34249288276

VL - 5

SP - 474

EP - 496

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -